ethnopharmacolog
relev
cordycep
sinensi
fungu
use
tradit
chines
medicin
tonic
sooth
lung
treatment
fatigu
respiratori
diseas
idiopath
pulmonari
fibrosi
chronic
irrevers
debilit
lung
diseas
show
fibroblastmyofibroblast
expans
excess
deposit
extracellular
matrix
interstitium
lead
breath
difficulti
previou
observ
reveal
partial
relief
lung
fibrosi
patient
suffer
sever
acut
respiratori
syndrom
sar
hypothes
cordycep
benefici
effect
lung
fibrosi
object
studi
explor
target
cordycep
relief
lung
fibrosi
anim
cell
model
gain
insight
underli
mechan
materi
method
rat
model
bleomycin
blm
induc
lung
fibrosi
fibrot
cell
model
transform
growth
factor
induct
employ
studi
result
reduct
infiltr
inflammatori
cell
deposit
fibroblast
loci
collagen
format
reactiv
oxygen
speci
product
cytokin
well
recoveri
imbal
observ
fibrot
rat
treatment
cordycep
prevent
day
blm
administr
therapeut
day
blm
regimen
fibrot
cell
model
transform
growth
factor
induct
human
lung
epitheli
acquir
mesenchym
phenotyp
increas
vimentin
express
concomit
decreas
ecadherin
epithelialmesenchym
transit
could
partial
revert
cordycepin
major
compon
cordycep
conclus
find
provid
insight
prevent
therapeut
potenti
cordycep
treatment
lung
fibrosi
idiopath
pulmonari
fibrosi
ipf
chronic
irrevers
debilit
lung
diseas
show
progress
scar
alveolar
tissu
lead
difficulti
breath
etiolog
diseas
larg
unknown
gener
consid
result
exposur
occup
andor
environment
risk
factor
act
concert
genet
suscept
fibrosi
antoni
et
al
million
peopl
worldwid
suffer
diseas
effect
treatment
cure
patient
die
lung
disord
within
year
diagnosi
verma
slutski
ipf
poor
prognosi
kinnula
normal
initi
inflamm
oxid
product
site
injuri
earli
stage
character
transdifferenti
epitheli
cell
accumul
fibroblastsmyofibroblast
format
fibroblast
foci
distort
lung
architectur
antoni
et
al
chang
epitheli
cobblestonelik
morpholog
myofibroblast
phenotyp
epithelialmesenchym
transit
emt
express
mesenchym
marker
vimentin
concomit
disrupt
ecadherin
junction
hallmark
ipf
mani
patient
howev
show
littl
evid
inflamm
antiinflammatori
treatment
littl
impact
diseas
willi
et
al
develop
progress
ipf
associ
activ
transform
growth
factor
induc
excess
product
deposit
collagen
extracellular
matrix
ecm
myofibroblast
well
disrupt
basement
membran
imbal
gelatinas
matrix
metalloproteinas
tissu
inhibitor
metalloproteinas
mmptimp
coward
et
al
coupl
mitochondri
dysfunct
reactiv
oxygen
speci
ro
product
also
aggrav
epitheli
cell
damag
idiopath
interstiti
disord
kabuyama
et
al
cordycep
sinensi
dongchongxiacao
abbrevi
cs
entomogen
fungu
whose
mycelia
grow
insid
pupa
larva
lepidoptera
moth
autumn
fruit
bodi
protrud
dead
insect
bodi
summer
renown
chines
medicin
sooth
lung
cs
often
use
treatment
respiratori
diseas
strengthen
immun
respons
also
report
antioxid
inhibitor
angiogenesi
cordycep
extract
shown
reliev
fibrosi
liver
da
et
al
zhu
et
al
zhu
et
al
kidney
chai
et
al
lung
wang
et
al
xu
et
al
inhibit
express
wang
et
al
xu
et
al
promot
collagen
degrad
li
et
al
dri
form
cs
contain
ergosterol
polysaccharid
glycoprotein
peptid
adenosin
cordycepin
deoxyadenosin
major
compon
li
et
al
tsai
et
al
demonstr
modul
cell
activ
alter
cell
morpholog
shin
et
al
sever
therapeut
strategi
target
variou
stage
fibrogenesi
investig
selman
et
al
object
present
studi
explor
target
cs
relief
lung
fibrosi
gain
insight
underli
mechan
dri
cordycep
sinensi
berk
sacc
contain
myceliafil
insect
bodi
fungal
fruit
bodi
origin
tibet
donat
eu
yan
sang
hong
kong
ltd
herbal
materi
authent
prof
songm
liang
school
chines
medicin
scm
chines
univers
hong
kong
voucher
specimen
deposit
herbarium
scm
herbal
drug
ground
powder
pass
siev
apertur
store
c
use
mimic
tradit
rout
administr
powder
suspend
distil
water
given
anim
intragastr
use
feed
tube
experi
perform
accord
hong
kong
guidelin
anim
welfar
protocol
approv
anim
research
ethic
committe
chines
univers
hong
kong
ref
no
male
spraguedawley
rat
week
old
hous
normal
laboratori
condit
c
lightdark
cycl
pulmonari
fibrosi
induc
intratrach
administr
singl
dose
mgkg
bleomycin
blm
nippon
kayaku
co
ltd
japan
dissolv
ml
physiolog
salin
bonniaud
et
al
day
pulmonari
fibrosi
develop
week
day
confirm
morpholog
chang
lung
accumul
excess
interstiti
collagen
chaudhari
et
al
intragastr
administr
cs
cours
fibrosi
develop
day
blm
administr
consid
prophylacticprevent
wherea
administr
cs
fibrosi
alreadi
develop
day
consid
therapeut
present
protocol
order
determin
optim
dose
cs
experi
perform
rat
equal
randomli
divid
four
group
name
bleomycininduc
fibrosi
rat
blm
group
b
lowdos
cs
treatment
gkg
bodi
weight
equival
human
dose
gkg
hui
chan
c
highdos
cs
treatment
gkg
bodi
weight
human
dose
normal
anim
receiv
vehicl
ctl
sham
control
group
anim
receiv
daili
intragastr
administr
ml
day
lung
tissu
collect
morpholog
biochem
analys
rat
surviv
blm
treatment
result
experi
show
potent
antifibrot
activ
group
dose
cs
gkg
therefor
use
subsequ
time
cours
studi
experi
see
scheme
thu
forti
rat
divid
five
group
four
group
receiv
intratrach
administr
blm
fifth
group
receiv
water
sham
control
ctl
among
four
group
blmtreat
rat
three
group
receiv
daili
dose
gkg
start
day
day
day
respect
sacrif
day
one
group
fibrot
rat
receiv
water
serv
posit
lung
fibrosi
control
rat
anaesthet
chloral
hydrat
g
bodi
weight
lung
remov
divid
two
halv
right
lung
use
differenti
alveolar
cell
count
maygrunwaldgiemsa
stain
left
lung
separ
two
portion
upper
portion
fix
paraformaldehyd
histopatholog
immunohistochem
analys
lower
portion
frozen
liquid
nitrogen
rna
analysi
histochem
analysi
ro
product
oxid
stress
alveolar
tissu
alveolar
cell
collect
right
lung
treat
untreat
rat
bronchoalveolar
lavag
physiolog
salin
cell
bronchoalveolar
lavag
fluid
balf
spread
clean
glass
slide
use
thermo
shandon
cytospin
centrifug
southern
product
ltd
cheshir
uk
airdri
fix
ethanol
stain
may
total
cell
number
percentag
macrophag
lymphocyt
neutrophil
eosinophil
bronchoalveolar
cell
cytospin
slide
record
paraformaldehydefix
lung
tissu
process
paraffin
embed
section
mm
thick
cut
use
microtom
follow
stain
haematoxylin
eosin
h
e
histopatholog
examin
section
stain
masson
trichrom
analyz
collagen
deposit
lung
tissu
immunohistochem
analysi
paraffin
section
dewax
xylen
rehydr
grade
ethanol
stain
antibodi
sigma
st
loui
usa
chemicon
merck
bioscienc
darmstadt
germani
calbiochem
temecula
ca
usa
alveolar
tissu
frozen
lung
section
mm
thick
cut
use
thermo
cryotom
shandon
southern
product
ltd
incub
intracellular
fluoresc
probe
dihydroethidium
mm
dhe
molecular
probe
eugen
usa
nadph
mm
lightprotect
humidifi
chamber
c
min
oxid
signal
ro
analyz
use
fluoresc
microscop
section
incub
mm
dhe
without
nadph
serv
posit
control
frozen
left
lung
tissu
rins
briefli
phosphat
buffer
total
protein
obtain
extract
lysi
buffer
mm
tri
buffer
ph
contain
mgml
pmsf
mgml
aprotinin
triton
proteinas
inhibitor
cocktail
protein
array
analysi
perform
use
rat
antibodi
array
raybiotech
inc
ga
usa
hydroxyprolin
assess
measur
collagen
deposit
lung
tissu
reddi
enwemeka
briefli
hydroxyprolin
lung
tissu
homogen
oxid
acet
buffer
contain
chloramin
sigma
usa
ehrlich
reagent
sigma
usa
min
develop
chromophor
optic
densiti
reaction
product
correspond
amount
collagen
measur
nm
use
elisa
micropl
reader
lung
tissu
remov
control
treat
rat
total
cellular
rna
isol
use
trizol
reagent
one
microgram
total
rna
directli
reversetranscrib
min
use
superscript
tm
preamplif
system
gibco
brl
grand
island
ny
usa
rt
product
subject
semiquantit
pcr
use
thermoprim
dna
polymeras
primer
procollagen
ia
gibcobrl
grand
island
ny
usa
tabl
support
inform
perkin
elmer
thermal
cycler
pcr
product
separ
agaros
gel
band
intens
measur
chemiluminesc
imag
analysi
system
use
fluorchem
softwar
alpha
innotech
corp
usa
intens
band
normal
intern
control
bactin
tabl
support
inform
liu
et
al
quantit
analysi
fibrot
protein
experi
quantit
real
time
rtpcr
method
taqman
probe
appli
biosystem
usa
use
tabl
support
inform
human
lung
carcinoma
epitheli
cell
atcc
cultur
medium
supplement
fetal
bovin
serum
iuml
penicillin
mgml
streptomycin
humidifi
co
incub
cell
seed
cm
cultur
dish
analysi
emt
protein
express
fibroblast
chang
induc
cell
treatment
ngml
h
emt
phenotyp
assess
cotreat
cell
cordycep
extract
mgml
mm
cordycepin
sigma
cell
assay
cordycep
powder
extract
cultur
medium
mgml
room
temperatur
centrifug
min
g
supernat
collect
cordycep
extract
ce
cell
assay
cell
lysat
collect
treatment
ce
cordycepin
h
subject
immunoblot
use
antibodi
epitheli
marker
protein
ecadherin
cell
signal
technol
danver
usa
mesenchym
marker
vimentin
lab
vision
thermo
fisher
scientif
fremont
ca
band
intens
quantifi
softwar
pd
quest
biorad
laboratori
hercul
ca
usa
normal
gapdh
cell
signal
technol
liu
et
al
data
analyz
oneway
analysi
varianc
follow
duncan
multipl
rang
test
detect
intragroup
intergroup
analysi
differ
use
graphpad
prism
sofewar
signific
differ
consid
lung
untreat
spraguedawley
rat
show
normal
alveolar
pattern
broncheoli
surround
alveolar
sac
alveoli
separ
alveolar
septa
fig
patholog
featur
rat
lung
blminduc
fibrosi
without
treatment
summar
tabl
signific
increas
p
infiltr
inflammatori
cell
includ
macrophag
neutrophil
eosinophil
lymphocyt
tabl
support
inform
presenc
peribronchi
interstiti
fibrosi
foci
region
promin
alveolar
tissu
rat
treatment
blm
day
fig
lung
intens
stain
collagen
fiber
demonstr
masson
trichrom
stain
fig
increas
mgmg
protein
vs
mgmg
protein
blm
untreat
sham
control
respect
observ
hydroxyprolin
analysi
collagen
fiber
fig
howev
fibrogen
remodel
intens
significantli
reduc
rat
treat
cs
week
associ
decreas
number
inflammatori
cell
p
tabl
support
inform
fibroprolif
foci
fig
g
h
level
collagen
reduc
group
respect
fig
indic
dosedepend
attenu
lung
fibrosi
blmrat
cs
treatment
two
week
sinc
reactiv
oxygen
speci
ro
tissu
remodel
regul
eg
metalloproteinas
mmp
inhibitor
timp
mediat
develop
blmmediat
lung
fibrosi
liu
et
al
situ
detect
ro
superoxid
rtpcr
analysi
regul
transcript
level
perform
mild
emiss
red
fluoresc
dhe
superoxid
anionspecif
indic
found
present
lung
tissu
untreat
rat
increas
intens
lung
tissu
blmtreat
rat
fig
support
inform
indic
strong
ro
product
fibrot
tissu
fig
support
inform
fluoresc
return
control
level
rat
fig
support
inform
invis
level
rat
fig
support
inform
collagen
profibrot
gene
activ
lung
fibrosi
thu
procollagen
transcript
mild
level
transcript
found
normal
lung
tissu
rtpcr
analysi
fibrogen
gene
express
dramat
lung
blmtreat
rat
suppress
cs
treatment
dosedepend
manner
fig
support
inform
find
partial
confirm
protein
array
analysi
cytokin
protein
analyz
protein
lung
tissu
blmrat
significantli
suppress
treatment
fig
support
inform
cordycep
treatment
group
two
week
attenu
blminduc
lung
fibrosi
dosedepend
manner
experi
fig
thu
highdos
use
subsequ
timedepend
experi
order
studi
preventiveprophylact
therapeut
effect
cs
treatment
given
lung
fibrosi
develop
ie
immedi
intragastr
blm
inject
respect
rat
receiv
treatment
day
day
day
respect
lung
tissu
subject
morpholog
biochem
analysi
focal
alveolar
hemorrhag
hemosiderin
deposit
mild
interstiti
inflamm
macrophag
eosinophil
neutrophil
lymphocyt
tabl
support
inform
well
peribronchonchi
fibrosi
observ
lung
tissu
blmrat
tabl
result
shown
fig
confirm
increas
lung
hydroxyprolin
content
blmrat
fold
comparison
untreat
sham
control
consist
find
experi
hydroxyprolin
product
significantli
suppress
untreat
control
level
cs
treatment
timeindepend
manner
fig
quantifi
chang
fibrogen
gene
treatment
variou
time
point
total
rna
collect
measur
quantit
real
time
rtpcr
result
suggest
increas
lung
tissu
blmrat
gradual
reduc
treatment
similar
suppress
fibrogen
gene
express
ie
observ
lung
tissu
three
timecours
treatment
fig
indic
signific
differ
among
differ
treatment
time
day
develop
fibrosi
treatment
group
respect
alveolar
epitheli
cell
normal
join
one
anoth
cell
junction
form
layer
cobblestonelik
appear
fig
high
express
ecadherin
cell
cultur
chang
spindl
fibroblastlik
phenotyp
presenc
ngml
h
fig
ecadherin
protein
decreas
undetect
level
untreat
control
group
respect
express
vimentin
increas
dramat
typic
featur
epithelialmesenchym
transit
order
determin
emt
inhibit
activ
ingredi
cordycep
eg
cordycepin
cell
cotreat
cordycep
extract
ce
mgml
mm
cordycepin
h
express
vimentin
ecadherin
found
revers
back
epitheli
phenotyp
cordycepin
ce
fig
implic
emt
inhibit
hand
low
level
cordycepin
crude
cordycep
extract
may
insuffici
revers
emt
process
idiopath
pulmonari
fibrosi
chronic
irrevers
debilit
lung
diseas
fibroblast
expans
excess
deposit
extracellular
matrix
interstitium
caus
breath
difficulti
million
peopl
worldwid
suffer
diseas
current
treatment
effect
patient
usual
die
lung
disord
within
year
diagnosi
antoni
et
al
c
sinensi
dongchongxiacao
folk
medicin
china
sooth
lung
treatment
fatigu
respiratori
diseas
well
modul
immun
respons
redox
balanc
inhibit
angiogenesi
relief
liver
fibrosi
clinic
partial
relief
lung
fibrosi
achiev
patient
suffer
sever
acut
respiratori
syndrom
sar
hui
chan
continu
studi
protectivetherapeut
mechan
cordycep
lung
fibrosi
analyz
morpholog
chang
lung
tissu
express
fibrogen
factor
rat
model
bleomycininduc
lung
fibrosi
order
gain
insight
treatment
hamper
diseas
total
rna
isol
lung
tissu
untreat
blmtreat
rat
revers
transcrib
cdna
pcr
use
taqman
probe
gene
n
increas
fibrot
gene
transcript
includ
procollagen
lung
tissu
blmtreat
rat
transcript
return
normal
level
timecours
treatment
lung
fibrosi
character
abnorm
prolifer
alveolar
mesenchym
cell
eg
myofibroblast
activ
inflammatori
cell
eg
neutrophil
macrophag
chaudhari
et
al
dunkern
et
al
cell
stress
produc
activ
characterist
accumul
matrix
protein
mainli
type
collagen
matrix
metalloproteinas
mmp
ipf
anim
model
blminduc
fibrosi
cutroneo
et
al
mmp
famili
ecm
degrad
enzym
inflammatori
cell
play
import
role
inflamm
tissu
remodel
yoshimura
et
al
member
mmp
famili
commonli
associ
ipf
bind
noncoval
specif
inhibitor
tissu
inhibitor
metalloproteinas
ratio
increas
increas
found
lung
tissu
blmrat
make
imbal
accumul
alveolar
ecm
commonli
found
human
fibrot
lung
kelli
jarjour
yoshimura
et
al
increas
mmptimp
favor
tissu
injuri
revers
may
associ
antifibrosi
kelli
jarjour
quantit
rtpcr
perform
experi
lung
fibrosi
allevi
decreas
timeindepend
manner
shown
cs
treatment
group
howev
noteworthi
transcript
suppress
greater
extent
result
signific
reduct
imbal
around
cs
treatment
group
thu
attenu
fibrot
injuri
blmrat
experi
imbal
induc
oxid
stress
yoshimura
et
al
allevi
antioxid
eg
egcg
sriram
et
al
resveratrol
sener
et
al
although
antioxid
activ
demonstr
cordycep
howev
unlik
caus
antifibrot
activ
yu
et
al
even
nacetylcystein
nac
strong
oxid
scaveng
slightli
allevi
fibrogenesi
prescrib
associ
corticosteroid
incur
lung
diseas
cottin
cordier
moeller
et
al
addit
cordycepin
activ
ingredi
isol
cordycep
show
signific
antioxid
activ
yu
et
al
implic
current
inform
pharmacolog
activ
cordycep
insuffici
explain
underli
antifibrot
mechan
among
wide
rang
biomed
properti
cordycep
antifibrot
activ
report
anim
fibrosi
model
kidney
zhao
li
liver
zhang
et
al
lung
wang
et
al
xu
et
al
receiv
pharmaceut
attent
fibrosi
irrevers
debilit
diseas
studi
cordycep
given
oral
either
suspens
aqueou
extract
nan
et
al
park
rang
gkgday
week
liu
et
al
gkgday
two
week
wang
et
al
also
demonstr
partial
relief
lung
fibrosi
patient
suffer
sever
acut
respiratori
syndrom
sar
follow
oral
administr
c
sinensi
powder
gday
week
hui
chan
c
sinensi
authent
dong
chong
xia
cao
speci
eg
c
militari
c
martiali
occasion
use
substitut
similar
biolog
activ
li
et
al
lower
market
valu
interestingli
similar
antifibrot
result
includ
decreas
product
collagen
restor
mmptimp
imbal
claim
treatment
liver
lung
fibrosi
extract
differ
cordycep
speci
ie
c
sinensi
c
militari
liu
shen
nan
et
al
wang
et
al
park
xu
et
al
common
bioactiv
ingredi
across
cordycep
speci
may
attribut
activ
dosedepend
antifibrot
activ
cordycep
suspens
demonstr
experi
cordycep
administ
develop
lung
fibrosi
similar
conclus
recent
made
xu
et
al
show
decreas
cultur
cs
signific
present
studi
perhap
find
allevi
lung
fibrosi
fibrosi
develop
experi
result
inhibit
critic
fibrosi
mediat
reduct
leukocyt
infiltr
collagen
product
recoveri
imbal
tissu
degrad
remodel
show
signific
differ
among
group
cs
treatment
day
result
implic
prevent
therapeut
potenti
cs
rat
model
lung
fibrosi
induc
blm
et
al
studi
requir
identifi
activ
compon
cordycep
respons
antifibrogen
mechan
addit
overexpress
mmptimp
fibrogen
cell
phenotyp
alter
cobblestoneshap
epitheli
cell
mobil
myofibroblast
ie
emt
format
fibroblast
foci
ipf
lung
promin
featur
experiment
human
lung
fibrosi
antoni
et
al
cell
lose
cellcel
junction
protein
ecadherin
express
mesenchym
marker
vimentin
asmooth
muscl
actin
asma
emt
thu
critic
develop
progress
fibrosi
inhibit
consid
chemotherapeut
target
fibrosi
preliminari
studi
show
revert
emt
cordycepin
mm
crude
cordycep
extract
cultur
cell
present
studi
probabl
attribut
rel
low
level
cordycepin
mgg
high
cytotox
ingredi
crude
cordycep
extract
unpublish
data
combin
pharmacokinet
pharmacolog
analysi
cordycep
extract
activ
ingredi
eg
cordycepin
adenosin
other
prevent
emt
may
provid
insight
antifibrogen
properti
cordycep
increas
evid
profibrot
role
growth
factor
eg
plateletderiv
growth
factor
pdgf
vascular
endotheli
growth
factor
vegf
hepatocyt
growth
factor
hgf
chaudhari
et
al
moeller
et
al
cytokin
eg
tumor
necrosi
factor
tnfa
interferongamma
ifng
moeller
et
al
solubl
hui
chan
scientif
research
laboratori
clinic
screen
therapeut
agent
target
factor
extens
studi
global
moeller
et
al
interest
find
cs
downregul
profibrot
factor
present
studi
also
suppress
solubl
hui
chan
vegf
inflammatori
cytokin
tnfa
ifng
li
et
al
antiapoptot
activ
shahe
et
al
wide
rang
activ
warrant
investig
potenti
develop
cs
therapeut
agent
lung
fibrosi
anim
result
suggest
c
sinensi
possess
prevent
also
therapeut
potenti
treatment
lung
fibrosi
one
activ
ingredi
cordycepin
partial
revers
epithelialmesenchym
transit
alveolar
epitheli
cell
donat
cordycep
sinensi
sampl
author
thank
ms
lisa
xian
technic
assist
